ReviewHuman vaccines & immunotherapeutics2026
Safety, immunogenicity, and effectiveness of the MAV/06 varicella vaccine: A comprehensive review of a new strain vaccine.
Review in Human vaccines & immunotherapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Most of licensed varicella vaccines are based on the Oka strain, while MAV/06 strain vaccines were exclusively developed by GC Biopharma Corp. in South Korea. This paper aims to summarize and present more than 30 y of accumulated evidence from about 40 unpublished and published studies on safety, immunogenicity, and effectiveness of MAV/06 vaccines. The safety of MAV/06 vaccines has been confirmed through various clinical trials and post-marketing studies. Outstanding humoral and cell-mediated immunogenicity of the MAV/06 vaccines has been demonstrated in diverse clinical trials and real-world studies. For example, a seroconversion rate of the MAV/06 vaccine (BARYCELA inj.) was close to 100%. Moreover, several after-approval epidemiological studies in Korean and Filipino children have supported the effectiveness of MAV/06 vaccines, although it remains to be further confirmed in future studies. In terms of safety, immunogenicity, and effectiveness, MAV/06 strain varicella vaccines are comparable to Oka strain vaccines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.